Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Merck (MRK.N) reportedly held talks to acquire MoonLake Immunotherapeutics (MLTX.O) for over $3 billion, according to the Financial Times, leading to a 19% surge in MoonLake's shares in extended trading. While Merck's initial nonbinding offer was rejected, discussions could resume, potentially driven by MoonLake's promising late-stage clinical data and Merck's need to diversify revenue streams ahead of Keytruda's patent expiration in 2028; however, there is no guarantee a deal will materialize and other buyers may emerge.

Analysis

Merck & Co. (MRK.N) reportedly engaged in discussions to acquire Swiss biotech MoonLake Immunotherapeutics (MLTX.O) for a sum exceeding $3 billion, a development that triggered a 19% surge in MoonLake's shares during extended trading. While an initial nonbinding offer from Merck earlier this year was purportedly rejected, the possibility of renewed negotiations remains, particularly as MoonLake approaches late-stage clinical data for its flagship drug, strengthening its strategic position. This potential acquisition aligns with Merck's pressing need to diversify its revenue streams, given the impending patent expiration of its blockbuster drug Keytruda in 2028 and reported declining revenues from its Gardasil vaccine in China. However, the report, characterized by a speculative tone, underscores that there is no certainty a transaction will materialize, and the emergence of other potential bidders for MoonLake cannot be ruled out, reflecting a common strategic imperative for large pharmaceutical companies to bolster their pipelines through M&A when facing patent cliffs.

Key Decisions for Investors

• Investors in MoonLake Immunotherapeutics (MLTX.O) should evaluate the current share price, which reflects a significant M&A premium, against the risk of the deal not proceeding, while also considering the potential for revised offers or alternative suitors as upcoming late-stage clinical data nears.
• For Merck (MRK.N) investors, this exploratory M&A activity highlights proactive measures to address future revenue gaps from Keytruda's patent expiration and Gardasil's challenges, making the terms and strategic integration of any potential acquisition critical focal points.
• Market participants should monitor for further announcements regarding this specific negotiation or the emergence of other interested parties, as such developments could significantly influence valuations for both companies and offer insights into the current appetite for biotech M&A.